TRANSCEND-CKD Trial Design: Retatrutide for Chronic Kidney Disease

Chronic Kidney Disease (CKD) is a progressive and debilitating condition affecting millions globally, often exacerbated by comorbidities like type 2 diabetes and obesity. It leads to a gradual decline in kidney function, increasing the risk of cardiovascular events and end-stage renal disease. Despite existing therapies, a significant unmet medical need persists for treatments that can effectively slow or halt CKD progression. This study addresses the critical knowledge gap regarding the potential of novel multi-agonist therapies like Retatrutide to protect kidney function in this high-risk population.

This paper primarily presents the detailed design and the baseline characteristics of the patient cohort enrolled in the TRANSCEND-CKD trial, rather than efficacy results. It outlines the trial's robust methodology aimed at assessing Retatrutide's impact on major kidney and cardiovascular outcomes. > The primary objective of the TRANSCEND-CKD trial is to determine if Retatrutide can significantly reduce the risk of kidney disease progression (defined as a composite of sustained eGFR decline, end-stage kidney disease, or renal death) or cardiovascular death in patients with CKD. Baseline data indicate that the enrolled participants have an average estimated glomerular filtration rate (eGFR) of approximately 45 mL/min/1.73m², with a mean body mass index (BMI) of 35 kg/m², and an average HbA1c of 7.5%, reflecting a population at high risk for disease progression. Approximately 60% of the enrolled patients have a history of established cardiovascular disease, further underscoring the trial's focus on comprehensive risk reduction in a vulnerable population.